These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25631653)

  • 21. NAFLD. Accurate quantification of hepatic fat--is it important?
    Adams LA
    Nat Rev Gastroenterol Hepatol; 2015 Mar; 12(3):126-7. PubMed ID: 25666645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.
    Ma DW; Arendt BM; Hillyer LM; Fung SK; McGilvray I; Guindi M; Allard JP
    Nutr Diabetes; 2016 Jul; 6(7):e220. PubMed ID: 27428872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psoriasis and Nonalcoholic Fatty Liver Disease.
    Carrascosa JM; Bonanad C; Dauden E; Botella R; Olveira-Martín A;
    Actas Dermosifiliogr; 2017; 108(6):506-514. PubMed ID: 28318525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnosis and treatment of non-alcoholic fatty liver disease.
    Altinbas A; Sowa JP; Hasenberg T; Canbay A
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between psoriasis and non-alcoholic fatty liver disease - Updated systematic review and adjusted meta-analysis.
    Phan K; Onggo J; Charlton O; Smith SD
    Australas J Dermatol; 2019 Nov; 60(4):e352-e355. PubMed ID: 30906989
    [No Abstract]   [Full Text] [Related]  

  • 29. Psoriasis and non-alcoholic fatty liver disease.
    Schön MP
    J Dtsch Dermatol Ges; 2021 Apr; 19(4):503-504. PubMed ID: 33861024
    [No Abstract]   [Full Text] [Related]  

  • 30. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
    Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
    J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nonalcoholic fatty liver disease and psoriasis].
    Rivera R; Vanaclocha F
    Actas Dermosifiliogr; 2010 Oct; 101(8):657-8. PubMed ID: 20965008
    [No Abstract]   [Full Text] [Related]  

  • 33. Non-alcoholic fatty liver disease.
    Pearce L
    Nurs Stand; 2016 Aug; 30(52):15. PubMed ID: 27641564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paediatric non-alcoholic fatty liver disease: an overview.
    AlKhater SA
    Obes Rev; 2015 May; 16(5):393-405. PubMed ID: 25753407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
    Yki-Järvinen H
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A concise review of non-alcoholic fatty liver disease.
    Than NN; Newsome PN
    Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatty liver: yet another silent killer.
    Javed M
    J Ayub Med Coll Abbottabad; 2014; 26(1):1-2. PubMed ID: 25358204
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.